The expression of CD44, CD90 and CD133 in response to cisplatin in hepatocellular cancer cells

Authors

  • Yaprak Donmez Cakıl Department of Histology and Embryology, Faculty of Medicine, Maltepe University, Istanbul, Turkey; Cancer and Stem Cell Research Center, Faculty of Medicine, Maltepe University, Istanbul, Turkey https://orcid.org/0000-0002-4605-1167
  • Zeynep Gunes Ozunal Cancer and Stem Cell Research Center, Faculty of Medicine, Maltepe University, Istanbul, Turkey; Department of Medical Pharmacology, Faculty of Medicine, Maltepe University, Istanbul, Turkey https://orcid.org/0000-0002-3060-1507
  • Damla Gokceoglu Kayalı Cancer and Stem Cell Research Center, Faculty of Medicine, Maltepe University, Istanbul, Turkey https://orcid.org/0000-0003-0674-090X
  • Ranan Gulhan Aktas Department of Histology and Embryology, Faculty of Medicine, Maltepe University, Istanbul, Turkey; Cancer and Stem Cell Research Center, Faculty of Medicine, Maltepe University, Istanbul, Turkey https://orcid.org/0000-0002-4474-7371

DOI:

https://doi.org/10.15584/ejcem.2021.1.3

Keywords:

cancer, cisplatin, hepatocellular, stem cells

Abstract

Introduction. Cancer is a leading cause of mortality. Hepatocellular cancer is one of the malignancies associated with poor outcome and resistance to pharmacotherapy. Cancer stem cells (CSCs) contribute to resistance to therapy and hence lead to the treatment failure of tumors.

Aim. This study aims to explore the expression of CSCs in response to cisplatin treatment in HepG2 hepatocellular cancer cell line.

Material and methods. Cell proliferation test, CCK-8, was used to evaluate the cell proliferation following cisplatin treatment for 72 hours. The expressions of CSC markers CD44, CD90, and CD133 were assessed by flow cytometric analysis.

Results. The results showed a dose-dependent decrease in cell proliferation and increased expression of CSC markers CD44 and CD90 in response to cisplatin.

Conclusion. Understanding the roles of CSC markers may point to new targets and therapeutic strategies to predict and overcome cisplatin resistance.

Downloads

Download data is not yet available.

References

Alfarouk KO, Stock C-M, Taylor S, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15(1):71.

Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2:141-160.

Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorg Chem. 2019;88:102925.

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-378.

Marin JJ, Macias RI, Monte MJ, et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers. 2020;12(6):1663.

Osaki A, Suda T, Kamimura K, et al. A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med. 2013;2(1):86-98.

Schulte L-A, López-Gil JC, Sainz B, Hermann PC. The Cancer Stem Cell in Hepatocellular Carcinoma. Cancers. 2020;12(3):684.

Wang K, Sun D. Cancer stem cells of hepatocellular carcinoma. Oncotarget. 2018;9(33):23306.

Asai R, Tsuchiya H, Amisaki M, et al. CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line. Cancer Med. 2019;8(2):773-782.

Yang ZF, Ho DW, Ng MN, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer cell. 2008;13(2):153-166.

Lu R, Zhao G, Yang Y, Jiang Z, Cai J, Hu H. Inhibition of CD133 overcomes cisplatin resistance through inhibiting PI3K/AKT/mTOR signaling pathway and autophagy in CD133-positive gastric cancer cells. Technol Cancer Res Treat. 2019;18:1533033819864311.

Kim BH, Park J-W, Kim JS, Lee S-K, Hong EK. Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma. Gut Liver. 2019;13(3):342-348.

Nör C, Zhang Z, Warner KA, et al. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia. 2014;16(2):137-146.

Bahnassy AA, Fawzy M, El-Wakil M, Zekri A-RN, Abdel-Sayed A, Sheta M. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data. Transl Res. 2015;165(3):396-406.

Quan YH, Lim J-Y, Choi BH, et al. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2019;83(3):399-410.

Yin J, Zhang H, Wu X, et al. CD44 inhibition attenuates EGFR signaling and enhances cisplatin sensitivity in human EGFR wild‑type non‑small‑cell lung cancer cells.

Wang XQ, Ongkeko WM, Chen L, et al. Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4–AKT–ATP‐binding cassette G2 pathway. Hepatology. 2010;52(2):528-539.

Liu Y-C, Yeh C-T, Lin K-H. Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies. Cells. 2020;9(6):1331.

Zhang H, Chang W, Li X, Zhang N, Kong J, Wang Y. Liver cancer stem cells are selectively enriched by low-dose cisplatin. Braz J Med Biol Res. 2014;47(6):478-482.

Zhang H, Yu T, Wen L, Wang H, Fei D, Jin C. Curcumin enhances the effectiveness of cisplatin by suppressing CD133+ cancer stem cells in laryngeal carcinoma treatment. Exp Ther Med. 2013;6(5):1317-1321.

Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351(4):820-824.

Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44(1):240-251.

Wiechert A, Saygin C, Thiagarajan PS, Rao VS, Hale JS, Gupta N, Hitomi M, Nagaraj AB, DiFeo A, Lathia JD, Reizes O. Cisplatin induces stemness in ovarian cancer. Oncotarget. 2016;7(21):30511-30522.

Thakur B, Ray P. Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop. J Exp Clin Cancer Res. 2017;36(1):164.

Downloads

Published

2021-03-30

How to Cite

Donmez Cakıl, Y., Ozunal, Z. G., Gokceoglu Kayalı, D., & Aktas, R. G. (2021). The expression of CD44, CD90 and CD133 in response to cisplatin in hepatocellular cancer cells. European Journal of Clinical and Experimental Medicine, 19(1), 18–22. https://doi.org/10.15584/ejcem.2021.1.3

Issue

Vol. 19 No. 1 (2021)

Section

ORIGINAL PAPERS

License

Copyright (c) 2021 European Journal of Clinical and Experimental Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.

All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.